OncoDaily GU (@OncoDailyGU) “ARTO long-term analysis Adding SBRT to abiraterone acetate + prednisone + ADT ma”

2026.07.07 13:52

ARTO long-term analysis Adding SBRT to abiraterone acetate + prednisone + ADT may improve outcomes in selected patients with oligometastatic CRPC. At 53-month median follow-up • OS: not reached vs 50 mo • HR 0.55; p=0.021 • bPFS: 44 vs 18 mo • rPFS: 44 vs 17 mo • 4-yr PC-specific survival: 86.6% vs 67.7% No new safety concerns were reported. @MicheleAquilano @alessiobruni @BarbaraJereczek @GabSimontacchi @PierluigiBonomo @ChadTangMD #ProstateCancer# #GUOncology# #SBRT# #Oncology#

显示更多